

**First clinical testing of Seracam® commences at the University of Malaya**

**London, UK 17 May 2023.** Serac Imaging Systems Limited (“Serac Imaging Systems” or “the Company”), the medtech company developing a portable hybrid gamma-optical camera for medical imaging, and the University of Malaya, today announce the start of clinical testing using the Seracam® camera.

The primary objective of this investigator sponsored study is to assess the correlation of images obtained using Seracam®, to those obtained with a current state-of-the-art gamma camera for nuclear medical imaging. The study is being led by Dr. Ng Aik Hao, senior lecturer at the University of Malaya and Professor Yeong Chai Hong, Professor at Taylor’s University, Malaysia, and is being carried out at the Kuala Lumpur Hospital and the University of Malaya Medical Centre.

**Dr. Ng Aik Hao, clinical medical physicist and senior lecturer at the University of Malaya** said they are excited to introduce this breakthrough imaging technology using Seracam®, to the Asian healthcare community, as well as being the first site to start using Seracam® in a clinical setting.

“It is anticipated that the hybrid gamma-optical camera will have many practical benefits, such as the visual overlay of a gamma image onto an anatomical optical image, which should allow the clinician or surgeon to make a better assessment of radioisotope localisation and hence improved diagnosis. This would be useful for a variety of procedures, particularly intra-operative imaging. We look forward to testing this in the clinic,” he added.

“We are delighted to be working with these experienced teams at the University of Malaya as they image patients using Seracam® for the first time. As well as the important comparative imaging data generated by this study, the patient and operator feedback on the user experience are essential as we continue to develop the camera. We are also particularly keen to understand the clinician’s perspective on the potential of this breakthrough technology to improve clinical practice in sentinel lymph node biopsy. We believe that the combination of the co-aligned gamma-optical hybrid imaging capability, alongside the compact size and portability of the camera have real potential to improve and expand nuclear imaging options, diagnosis, and outcomes for patients,” said **Chief Executive Officer of Serac Imaging Systems, Mark Rosser.**

The study will involve a comparison of the visualisation of radiopharmaceutical uptake between Seracam® and a standard gamma camera, using images obtained from the same patient on the same day. The study is expected to involve up to 150 patients and may be extended to include other clinical departments forming a multi-site clinical trial.

This is the first of a network of clinical sites which are due to commence testing this year.

- ENDS -

**For more information, please contact:**

Serac Imaging Systems Ltd

[www.seracimagingsystems.com](http://www.seracimagingsystems.com)

Mark Rosser, Chief Executive Officer

+44 (0)208 948 0000

[info@seraclifesciences.com](mailto:info@seraclifesciences.com)

Francetta Carr, Communications

+44 (0)7711 010 820

[francettacarr@seraclifesciences.com](mailto:francettacarr@seraclifesciences.com)

## **Notes to Editors**

### **About Serac Imaging Systems and Seracam®**

Serac Imaging Systems Ltd is the medtech company developing a portable hybrid gamma-optical camera for medical imaging. Our lead product is Seracam® which is in development to bring the benefits of high-resolution molecular imaging to a patient's bedside, instead of being confined for use in a hospital's nuclear medicine imaging department. A further unique feature of this technological approach is the overlay of a gamma image with an optical image of the same anatomical location under examination. Such portable and enhanced imaging technology has the potential to help clinicians make better, more informed and more timely treatment decisions. Seracam® is a UK and EU registered trademark.

**Seracam® is for investigational use only and has not been cleared or approved by the FDA or UK and European regulatory authorities.**

Serac Imaging Systems Ltd is a wholly owned subsidiary of Serac Life Sciences Limited.

For further details, please see [www.seracimaging.com](http://www.seracimaging.com)

### **About molecular imaging**

Molecular imaging is a type of medical imaging that provides unique insights into what is happening inside the body at the cellular and molecular level helping physicians to deliver personalised medicine by delivering the right treatment to the right patient at the right time. Unlike other medical imaging technologies such as x-rays, computed tomography (CT) and ultrasound (US) which provide structural images, molecular imaging allows physicians to see how cells, tissues and organs are functioning and to measure chemical and biological processes without having to resort to biopsy or surgery.